Atossa Therapeutics (ATOS) News Today $1.39 -0.01 (-0.71%) (As of 10/10/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment ContinuumOctober 1, 2024 | globenewswire.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 3,160.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 411,667 shares of theSeptember 25, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200-Day Moving Average of $1.41Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average of $1.41September 19, 2024 | marketbeat.comAscendiant Capital Markets Boosts Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.50Ascendiant Capital Markets increased their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a research note on Wednesday.September 11, 2024 | marketbeat.comAtossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast CancerSeptember 10, 2024 | globenewswire.comAtossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.com2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%August 29, 2024 | msn.comAtossa Therapeutics Granted Additional Patent Protection for EndoxifenAugust 28, 2024 | globenewswire.comAtossa and Quantum Leap dose first subject in breast cancer therapy trialAugust 22, 2024 | finance.yahoo.comAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerAugust 21, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerAugust 21, 2024 | globenewswire.comAtossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public RelationsAugust 20, 2024 | globenewswire.comFY2024 Earnings Estimate for Atossa Therapeutics, Inc. (NASDAQ:ATOS) Issued By Cantor FitzgeraldAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Atossa Therapeutics in a report released on Tuesday, August 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($0.22) per share for tAugust 15, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPSAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01.August 13, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Cut to "Sell" at StockNews.comStockNews.com downgraded Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Monday.August 12, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Atossa Therapeutics (NASDAQ:ATOS)HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Atossa Therapeutics in a research report on Monday.August 12, 2024 | marketbeat.comAtossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200 Day Moving Average of $1.29Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.29July 25, 2024 | marketbeat.comAtossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast CancerJuly 22, 2024 | globenewswire.com3 Dirt-Cheap Drug Developers With Blockbuster PotentialJuly 11, 2024 | investorplace.com3 Penny Stock Moonshots with 300%+ Upside Potential by 2025July 3, 2024 | investorplace.comAtossa Therapeutics names Heather Rees as CFOJuly 2, 2024 | proactiveinvestors.comAtossa Therapeutics Appoints Heather Rees as Chief Financial OfficerJuly 2, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and set a $6.00 price objective on shares of Atossa Therapeutics in a research report on Friday.June 28, 2024 | marketbeat.comAtossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerJune 28, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Atossa Therapeutics in a research report on Thursday.June 20, 2024 | marketbeat.comAtossa Set to Join Russell 3000® Index Effective June 28, 2024June 17, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Shares Pass Above 200 Day Moving Average of $1.20Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving Average of $1.20June 14, 2024 | marketbeat.comMeme Mania Meets Medicine: 3 Biotech Stocks Primed to SoarJune 7, 2024 | investorplace.comAtossa Therapeutics (NASDAQ:ATOS) Price Target Increased to $6.25 by Analysts at Ascendiant Capital MarketsAscendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $6.00 to $6.25 and gave the company a "buy" rating in a research report on Thursday.June 6, 2024 | marketbeat.comAtossa to Present at the Sidoti Small-Cap Investor ConferenceJune 5, 2024 | globenewswire.comAtossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelMay 28, 2024 | globenewswire.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 20, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 17, 2024 | investorplace.comShort Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Decreases By 7.4%Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the target of a large decline in short interest in April. As of April 30th, there was short interest totalling 11,440,000 shares, a decline of 7.4% from the April 15th total of 12,350,000 shares. Based on an average daily volume of 1,780,000 shares, the days-to-cover ratio is presently 6.4 days.May 16, 2024 | marketbeat.comAtossa Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ATOS)Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Analysts at HC Wainwright boosted their Q2 2024 earnings estimates for Atossa Therapeutics in a research note issued on Monday, May 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.05) per shareMay 16, 2024 | marketbeat.comAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | finanznachrichten.deAtossa Therapeutics gives final dose in breast cancer prevention studyMay 15, 2024 | proactiveinvestors.comAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialMay 15, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPSAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) issued its earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02.May 15, 2024 | marketbeat.comAtossa Therapeutics’ Endoxifen Shows Promising Phase 2 Results, Secures Buy RatingMay 15, 2024 | markets.businessinsider.comAtossa Therapeutics files for $100M mixed shelf offeringMay 13, 2024 | msn.comATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024May 13, 2024 | msn.comAtossa Therapeutics (NASDAQ:ATOS) Given New $6.00 Price Target at HC WainwrightHC Wainwright boosted their price objective on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company a "buy" rating in a report on Monday.May 13, 2024 | marketbeat.comAtossa Therapeutics Inc (ATOS) Q1 2024 Earnings: Aligns with Analyst Projections Amidst ...May 13, 2024 | finance.yahoo.comAtossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1May 13, 2024 | proactiveinvestors.comAtossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comShhh! 3 Secret Penny Stocks Flying Below Wall Street's RadarMay 9, 2024 | investorplace.comAtossa Therapeutics welcomes updated breast cancer screening guidelinesMay 7, 2024 | proactiveinvestors.comAtossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesMay 7, 2024 | globenewswire.com Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. ATOS Media Mentions By Week ATOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼1.870.72▲Average Medical News Sentiment ATOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼22▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNOA News EYEG News ABUS News ETNB News RAPP News ORIC News ABVX News ARCT News ALGS News REPL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 10/11/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATOS Stock Alerts